Pluripotent stem cells for Parkinson's disease: Progress and challenges

Stem Cell Research and Therapy

Volumn 4, Issue 2, 2013, Pages

  Zeng, Xianmin ^a   Couture, Larry A ^b  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AADC PROTEIN; CELL PROTEIN; DOPAMINE; DOPAMINE TRANSPORTER; FIBROBLAST GROWTH FACTOR 8; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HEPATOCYTE NUCLEAR FACTOR 3BETA; NERVE CELL ADHESION MOLECULE; NUCLEAR RECEPTOR RELATED FACTOR 1; PROTEIN GIRK2; PROTEIN LMX1A; PROTEIN LMX1B; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR PITX3; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL COUNT; CELL EXPANSION; CELL PROLIFERATION; CELL PURIFICATION; CELL SELECTION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CLINICAL EFFECTIVENESS; COCULTURE; CULTURE MEDIUM; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; EMBRYOID BODY; EMBRYONIC STEM CELL; GRAFT REJECTION; HUMAN; INTERMETHOD COMPARISON; INTRACELLULAR SIGNALING; NERVE CELL DIFFERENTIATION; NEURAL STEM CELL; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PLURIPOTENT STEM CELL; PLURIPOTENT STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PURIFICATION; REVIEW; STEM CELL TRANSPLANTATION; STROMA CELL; ANIMAL; BIOLOGICAL THERAPY; CYTOLOGY; METABOLISM; PATHOLOGY; TRANSPLANTATION;

ANIMALS; CELL- AND TISSUE-BASED THERAPY; DOPAMINERGIC NEURONS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; PARKINSON DISEASE; PLURIPOTENT STEM CELLS;

EID: 84876102476     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt173     Document Type: Review

References (53)

1. The nigrostriatal system in Parkinson's disease. Graybiel AM, Hirsch EC, Agid Y, Adv Neurol 1990 53 17 29 1978514
2. Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease. Lindvall O, Kokaia Z, Trends Pharmacol Sci 2009 30 260 267 10.1016/j.tips.2009.03.001 19362379
3. Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next? Politis M, BMC Med 2010 8 80 10.1186/1741-7015-8-80 21126348
4. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Perlow MJ, Freed WJ, Hoffer BJ, Seiger A, Olson L, Wyatt RJ, Science 1979 204 643 647 10.1126/science.571147 571147 (Pubitemid 9221523)
5. Reinnervation of the denervated striatum by substantia nigra transplants: functional consequences as revealed by pharmacological and sensorimotor testing. Björklund A, Dunnett SB, Stenevi U, Lewis ME, Iversen SD, Brain Res 1980 199 307 333 10.1016/0006-8993(80)90692-7 7417786 (Pubitemid 10055937)
6. Restoration of dopaminergic function by grafting of fetal rat substantia nigra to the caudate nucleus: long-term behavioral, biochemical, and histochemical studies. Freed WJ, Perlow MJ, Karoum F, Seiger A, Olson L, Hoffer BJ, Wyatt RJ, Ann Neurol 1980 8 510 519 10.1002/ana.410080508 7436393 (Pubitemid 11209236)
7. Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats. Studer L, Tabar V, McKay RD, Nat Neurosci 1998 1 290 295 10.1038/1105 10195162
8. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Bjorklund LM, Sánchez-Pernaute R, Chung S, Andersson T, Chen IY, McNaught KS, Brownell AL, Jenkins BG, Wahlestedt C, Kim KS, Isacson O, Proc Natl Acad Sci USA 2002 99 2344 2349 10.1073/pnas.022438099 11782534 (Pubitemid 34169063)
9. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Kim JH, Auerbach JM, Rodríguez-Gómez JA, Velasco I, Gavin D, Lumelsky N, Lee SH, Nguyen J, Sánchez-Pernaute R, Bankiewicz K, McKay R, Nature 2002 418 50 56 10.1038/nature00900 12077607 (Pubitemid 34742566)
10. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. Freed CR, Breeze RE, Rosenberg NL, Schneck SA, Kriek E, Qi JX, Lone T, Zhang YB, Snyder JA, Wells TH, Ramig LO, Thompson L, Mazziotta JC, Huang SC, Grafton ST, Brooks D, Sawle G, Schroter G, Ansari AA, N Engl J Med 1992 327 1549 1555 10.1056/ NEJM199211263272202 1435881
11. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Lindvall O, Sawle G, Widner H, Rothwell JC, Bjorklund A, Brooks D, Brundin P, Frackowiak R, Marsden CD, Odin P, Rehncrona S, Ann Neurol 1994 35 172 180 10.1002/ana.410350208 8109898 (Pubitemid 24050152)
12. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. Kordower JH, Freeman TB, Snow BJ, Vingerhoets FJG, Mufson EJ, Sanberg PR, Hauser RA, Smith DA, Nauert GM, Perl DP, Olanow CW, N Engl J Med 1995 332 1118 1124 10.1056/NEJM199504273321702 7700284
13. Dopamine cell implantation in Parkinson's disease: long-term clinical and (18)F-FDOPA PET outcomes. Ma Y, Tang C, Chaly T, Greene P, Breeze R, Fahn S, Freed C, Dhawan V, Eidelberg D, J Nucl Med 2010 51 7 15 10.2967/jnumed.109. 066811 20008998
14. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski JQ, Eidelberg D, Fahn S, N Engl J Med 2001 344 710 719 10.1056/NEJM200103083441002 11236774 (Pubitemid 32204988)
15. Future of cell and gene therapies for Parkinson's disease. Isacson O, Kordower JH, Ann Neurol 2008 64 Suppl 2 122 138 19127583
16. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Rehncrona S, Bjorklund A, Lindvall O, Piccini P, Sci Transl Med 2010 2 38ra46 10.1126/scitranslmed.3000976 20592420
17. Assessing fetal nerve cell grafts in Parkinson's disease. Braak H, Del Tredici K, Nat Med 2008 14 483 485 10.1038/nm0508-483 18463652 (Pubitemid 351655198)
18. Embryonic stem cell lines derived from human blastocysts. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM, Science 1998 282 1145 1147 9804556 (Pubitemid 28516247)
19. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Hargus G, Cooper O, Deleidi M, Levy A, Lee K, Marlow E, Yow A, Soldner F, Hockemeyer D, Hallett PJ, Osborn T, Jaenisch R, Isacson O, Proc Natl Acad Sci USA 2010 107 15921 15926 10.1073/pnas.1010209107 20798034
20. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A, Cooper O, Mitalipova M, Isacson O, Jaenisch R, Cell 2009 136 964 977 10.1016/j.cell.2009.02.013 19269371
21. Derivation of midbrain dopamine neurons from human embryonic stem cells. Perrier AL, Tabar V, Barberi T, Rubio ME, Bruses J, Topf N, Harrison NL, Studer L, Proc Natl Acad Sci USA 2004 101 12543 12548 10.1073/pnas.0404700101 15310843 (Pubitemid 39122060)
22. Dopaminergic differentiation of human embryonic stem cells. Zeng X, Cai J, Chen J, Luo Y, You ZB, Fotter E, Wang Y, Harvey B, Miura T, Backman C, Chen GJ, Rao MS, Freed WJ, Stem Cells 2004 22 925 940 10.1634/stemcells.22-6-925 15536184 (Pubitemid 39507080)
23. Transplantation of human embryonic stem cell-derived neural progenitors improves behavioral deficit in Parkinsonian rats. Ben-Hur T, Idelson M, Khaner H, Pera M, Reinhartz E, Itzik A, Reubinoff BE, Stem Cells 2004 22 1246 1255 10.1634/stemcells.2004-0094 15579643 (Pubitemid 39636402)
24. Human embryonic stem cell-derived dopaminergic neurons reverse functional deficit in parkinsonian rats. Yang D, Zhang ZJ, Oldenburg M, Ayala M, Zhang SC, Stem Cells 2008 26 55 63 10.1634/stemcells.2007-0494 17951220
25. Noggin enhances dopamine neuron production from human embryonic stem cells and improves behavioral outcome after transplantation into Parkinsonian rats. Chiba S, Lee YM, Zhou W, Freed CR, Stem Cells 2008 26 2810 2820 10.1634/stemcells.2008-0085 18772316
26. Xeno-free defined conditions for culture of human embryonic stem cells, neural stem cells and dopaminergic neurons derived from them. Swistowski A, Peng J, Han Y, Swistowska AM, Rao MS, Zeng X, PLoS One 2009 4 6233 10.1371/journal.pone.0006233 19597550
27. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Roy NS, Cleren C, Singh SK, Yang L, Beal MF, Goldman SA, Nat Med 2006 12 1259 1268 10.1038/nm1495 17057709 (Pubitemid 44706928)
28. In vitro and in vivo analyses of human embryonic stem cell-derived dopamine neurons. Park CH, Minn YK, Lee JY, Choi DH, Chang MY, Shim JW, Ko JY, Koh HC, Kang MJ, Kang JS, Rhie DJ, Lee YS, Son H, Moon SY, Kim KS, Lee SH, J Neurochem 2005 92 1265 1276 10.1111/j.1471-4159.2004.03006.x 15715675 (Pubitemid 40344315)
29. Generation of dopaminergic neurons in vitro from human embryonic stem cells treated with neurotrophic factors. Park S, Lee KS, Lee YJ, Shin HA, Cho HY, Wang KC, Kim YS, Lee HT, Chung KS, Kim EY, Lim J, Neurosci Lett 2004 359 99 103 10.1016/j.neulet.2004.01.073 15050721 (Pubitemid 38446648)
30. Generation of tyrosine hydroxylase positive neurons from human embryonic stem cells after coculture with cellular substrates and exposure to GDNF. Buytaert-Hoefen KA, Alvarez E, Freed CR, Stem Cells 2004 22 669 674 10.1634/stemcells.22-5-669 15342931 (Pubitemid 39166925)
31. Differentiation of human embryonic stem cells to dopaminergic neurons in serum-free suspension culture. Schulz TC, Noggle SA, Palmarini GM, Weiler DA, Lyons IG, Pensa KA, Meedeniya AC, Davidson BP, Lambert NA, Condie BG, Stem Cells 2004 22 1218 1238 10.1634/stemcells.2004-0114 15579641 (Pubitemid 39636400)
32. Directed differentiation of dopaminergic neuronal subtypes from human embryonic stem cells. Yan Y, Yang D, Zarnowska ED, Du Z, Werbel B, Valliere C, Pearce RA, Thomson JA, Zhang SC, Stem Cells 2005 23 781 790 10.1634/stemcells. 2004-0365 15917474 (Pubitemid 40791793)
33. Stage-specific role for shh in dopaminergic differentiation of human embryonic stem cells induced by stromal cells. Swistowska AM, da Cruz AB, Han Y, Swistowski A, Liu Y, Shin S, Zhan M, Rao MS, Zeng X, Stem Cells Dev 2010 19 71 82 10.1089/scd.2009.0107 19788370
34. Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Lee SH, Lumelsky N, Studer L, Auerbach JM, McKay RD, Nat Biotechnol 2000 18 675 679 10.1038/76536 10835609 (Pubitemid 30415305)
35. Neural progenitors from human embryonic stem cells. Reubinoff BE, Itsykson P, Turetsky T, Pera MF, Reinhartz E, Itzik A, Ben-Hur T, Nat Biotechnol 2001 19 1134 1140 10.1038/nbt1201-1134 11731782 (Pubitemid 33115699)
36. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Zhang SC, Wernig M, Duncan ID, Brüstle O, Thomson JA, Nat Biotechnol 2001 19 1129 1133 10.1038/nbt1201-1129 11731781 (Pubitemid 33115698)
37. Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Kawasaki H, Mizuseki K, Nishikawa S, Kaneko S, Kuwana Y, Nakanishi S, Nishikawa SI, Sasai Y, Neuron 2000 28 31 40 10.1016/S0896-6273(00)00083-0 11086981
38. Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. Takagi Y, Takahashi J, Saiki H, Morizane A, Hayashi T, Kishi Y, Fukuda H, Okamoto Y, Koyanagi M, Ideguchi M, Hayashi H, Imazato T, Kawasaki H, Suemori H, Omachi S, Iida H, Itoh N, Nakatsuji N, Sasai Y, Hashimoto N, J Clin Invest 2005 115 102 109 15630449 (Pubitemid 40385510)
39. A novel combination of factors, termed SPIE, which promotes dopaminergic neuron differentiation from human embryonic stem cells. Vazin T, Becker KG, Chen J, Spivak CE, Lupica CR, Zhang Y, Worden L, Freed WJ, PLoS One 2009 4 6606 10.1371/journal.pone.0006606 19672298
40. Efficient derivation of functional floor plate tissue from human embryonic stem cells. Fasano CA, Chambers SM, Lee G, Tomishima MJ, Studer L, Cell Stem Cell 2010 6 336 347 10.1016/j.stem.2010.03.001 20362538
41. Differentiation of human ES and Parkinson's disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid. Cooper O, Hargus G, Deleidi M, Blak A, Osborn T, Marlow E, Lee K, Levy A, Perez-Torres E, Yow A, Isacson O, Mol Cell Neurosci 2010 45 258 266 10.1016/j.mcn.2010.06.017 20603216
42. Dopaminergic neurons derived from human induced pluripotent stem cells survive and integrate into 6-OHDA-lesioned rats. Cai J, Yang M, Poremsky E, Kidd S, Schneider JS, Iacovitti L, Stem Cells Dev 2010 19 1017 1023 10.1089/scd.2009.0319 19824823
43. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Wernig M, Zhao JP, Pruszak J, Hedlund E, Fu D, Soldner F, Broccoli V, Constantine-Paton M, Isacson O, Jaenisch R, Proc Natl Acad Sci USA 2008 105 5856 5861 10.1073/pnas.0801677105 18391196 (Pubitemid 351758462)
44. Host-dependent tumorigenesis of embryonic stem cell transplantation in experimental stroke. Erdö F, Bührle C, Blunk J, Hoehn M, Xia Y, Fleischmann B, Föcking M, Küstermann E, Kolossov E, Hescheler J, Hossmann KA, Trapp T, J Cereb Blood Flow Metab 2003 23 780 785 12843782 (Pubitemid 36818686)
45. Selection of embryonic stem cell-derived enhanced green fluorescent protein-positive dopamine neurons using the tyrosine hydroxylase promoter is confounded by reporter gene expression in immature cell populations. Hedlund E, Pruszak J, Ferree A, Viñuela A, Hong S, Isacson O, Kim KS, Stem Cells 2007 25 1126 1135 10.1634/stemcells.2006-0540 17234989 (Pubitemid 46684872)
46. Girk2 expression in the ventral midbrain, cerebellum, and olfactory bulb and its relationship to the murine mutation weaver. Schein JC, Hunter DD, Roffler-Tarlov S, Dev Biol 1998 204 432 450 10.1006/dbio.1998.9076 9882481 (Pubitemid 29024490)
47. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, Hon G, Antosiewicz-Bourget J, O'Malley R, Castanon R, Klugman S, Downes M, Yu R, Stewart R, Ren B, Thomson JA, Evans RM, Ecker JR, Nature 2011 471 68 73 10.1038/nature09798 21289626
48. Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet Beta cells. Bar-Nur O, Russ HA, Efrat S, Benvenisty N, Cell Stem Cell 2011 9 17 23 10.1016/j.stem.2011.06.007 21726830
49. Efficient generation of functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions. Swistowski A, Peng J, Liu Q, Mali P, Rao MS, Cheng L, Zeng X, Stem Cells 2010 28 1893 1904 10.1002/stem.499 20715183
50. Directed differentiation of dopamine neurons from human pluripotent stem cells. Ma L, Liu Y, Zhang SC, Methods Mol Biol 2011 767 411 418 10.1007/978-1-61779-201-4-30 21822892
51. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Mayshar Y, Ben-David U, Lavon N, Biancotti JC, Yakir B, Clark AT, Plath K, Lowry WE, Benvenisty N, Cell Stem Cell 2010 7 521 531 10.1016/j.stem.2010.07.017 20887957
52. Copy number variation and selection during reprogramming to pluripotency. Hussein SM, Batada NN, Vuoristo S, Ching RW, Autio R, Närvä E, Ng S, Sourour M, Hämäläinen R, Olsson C, Lundin K, Mikkola M, Trokovic R, Peitz M, Brüstle O, Bazett-Jones DP, Alitalo K, Lahesmaa R, Nagy A, Otonkoski T, Nature 2011 471 58 62 10.1038/nature09871 21368824
53. Extended passaging increases the efficiency of neural differentiation from induced pluripotent stem cells. Koehler KR, Tropel P, Theile JW, Kondo T, Cummins TR, Viville S, Hashino E, BMC Neurosci 2011 12 82 10.1186/1471-2202-12- 82 21831300